论文部分内容阅读
目的探讨紫杉醇联合奥沙利铂和氟尿嘧啶(P0F方案)治疗晚期胃癌的疗效与安全性。方法 28例晚期胃癌患者采用P0F方案进行化疗:紫杉醇85 mg/m2,第1,8天,静脉滴注;奥沙利铂130mg/m2,第1天,静脉滴注;氟尿嘧啶500 mg/m2,第1至第5天,静脉滴注。21天为1个周期,2个周期评价疗效。患者在治疗前和治疗后均接受生存质量量表(QOL)测评,并记录患者在治疗后的不良反应。结果 28例患者的总有效率为67.9%,其中初治患者15例,有效率为80.0%,复治患者13例,有效率为53.8%,两者之间差异有统计学意义(P<0.05)。治疗后患者的躯体、情绪、认知、疼痛及社会功能分值均高于治疗前,且差异有统计学意义(P<0.05)。治疗2个周期后,主要的不良反应为骨髓抑制、胃肠道反应和外周神经毒性等,经对症治疗后,患者均能耐受。结论晚期胃癌患者采用紫杉醇、奥沙利铂和氟尿嘧啶联合治疗,可提高疗效,且不良反应可对症治疗,值得临床进一步推广。
Objective To investigate the efficacy and safety of paclitaxel plus oxaliplatin and fluorouracil (P0F regimen) in the treatment of advanced gastric cancer. Methods 28 patients with advanced gastric cancer were treated with P0F regimen: paclitaxel 85 mg / m2, intravenous drip on days 1 and 8, oxaliplatin 130 mg / m2 on day 1, intravenous infusion of fluorouracil 500 mg / m2, On days 1 to 5, intravenous drip. 21 days for a cycle, 2 cycles evaluation of efficacy. Patients were assessed for quality of life (QOL) before and after treatment, and the adverse reactions of the patients after treatment were recorded. Results The total effective rate of the 28 patients was 67.9%, of which 15 patients were newly diagnosed, the effective rate was 80.0%, and 13 patients were retreatment, the effective rate was 53.8%, the difference was statistically significant (P <0.05 ). After treatment, the score of somatosensory, emotional, cognitive, pain and social function were higher than before treatment, and the difference was statistically significant (P <0.05). After 2 cycles of treatment, the main adverse reactions were myelosuppression, gastrointestinal reactions and peripheral neurotoxicity. After symptomatic treatment, patients were able to tolerate. Conclusions The combination of paclitaxel, oxaliplatin and fluorouracil in patients with advanced gastric cancer can improve the curative effect, and adverse reactions can be symptomatic treatment, which is worth further clinical promotion.